• How Breast Cancer Patients Metabolize Tamoxifen Affects Outcomes

A new study confirms that a patient’s ability to metabolize the breast cancer drug tamoxifen affects the outcome of her treatment. Researchers at the Mayo Clinic Cancer Center and the Austrian Breast and Colorectal Cancer Study Group confirm that women with early breast cancer who are treated with tamoxifen and have genetic alterations in the liver enzyme CYP2D6 have a higher likelihood of cancer recurrence. Lead author Matthew Goetz, M.D., says,“Our findings confirm that in early breast cancer treated with tamoxifen, genetic alterations in CYP2D6 lead to a higher likelihood of recurrence and death.” 

The study is published in the journal Clinical Cancer Research

Click here for news release

Sound bites with Dr. Goetz are available in the downloads above

Expert title for broadcast cg: Dr. Matthew Goetz, Mayo Clinic Oncologist


Related articles